var data={"title":"Noninfectious complications following lung transplantation","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Noninfectious complications following lung transplantation</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/contributors\" class=\"contributor contributor_credentials\">Vivek N Ahya, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/contributors\" class=\"contributor contributor_credentials\">Steven M Kawut, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/contributors\" class=\"contributor contributor_credentials\">Elbert P Trulock, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 21, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lung transplantation is an important therapeutic option for select patients with end-stage lung disease and offers the potential for improved quality of life and long-term survival. Unfortunately, the lung transplant recipient is at risk for developing numerous infectious and noninfectious complications that threaten these objectives, including anastomotic problems, allograft rejection, primary graft dysfunction, phrenic nerve injury, pleural complications, venous thromboembolism, post-transplant malignancy, and recurrent primary disease.</p><p>General noninfectious complications of lung transplantation will be reviewed here. Other transplant-related complications, such as airway anastomotic complications, gastroesophageal reflux, reduced muscle strength, infection, and allograft rejection, are discussed separately. (See <a href=\"topic.htm?path=airway-complications-after-lung-transplantation\" class=\"medical medical_review\">&quot;Airway complications after lung transplantation&quot;</a> and <a href=\"topic.htm?path=physiologic-changes-following-lung-transplantation\" class=\"medical medical_review\">&quot;Physiologic changes following lung transplantation&quot;</a> and <a href=\"topic.htm?path=fungal-infections-following-lung-transplantation\" class=\"medical medical_review\">&quot;Fungal infections following lung transplantation&quot;</a> and <a href=\"topic.htm?path=bacterial-infections-following-lung-transplantation\" class=\"medical medical_review\">&quot;Bacterial infections following lung transplantation&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-cytomegalovirus-infection-in-lung-transplant-recipients\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients&quot;</a> and <a href=\"topic.htm?path=viral-infections-following-lung-transplantation\" class=\"medical medical_review\">&quot;Viral infections following lung transplantation&quot;</a> and <a href=\"topic.htm?path=evaluation-and-treatment-of-acute-lung-transplant-rejection\" class=\"medical medical_review\">&quot;Evaluation and treatment of acute lung transplant rejection&quot;</a> and <a href=\"topic.htm?path=chronic-lung-transplant-rejection-bronchiolitis-obliterans\" class=\"medical medical_review\">&quot;Chronic lung transplant rejection: Bronchiolitis obliterans&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H589167\"><span class=\"h1\">ALLOGRAFT REJECTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute and chronic lung transplant rejection are discussed separately. (See <a href=\"topic.htm?path=evaluation-and-treatment-of-acute-lung-transplant-rejection\" class=\"medical medical_review\">&quot;Evaluation and treatment of acute lung transplant rejection&quot;</a> and <a href=\"topic.htm?path=evaluation-and-treatment-of-antibody-mediated-lung-transplant-rejection\" class=\"medical medical_review\">&quot;Evaluation and treatment of antibody-mediated lung transplant rejection&quot;</a> and <a href=\"topic.htm?path=chronic-lung-transplant-rejection-bronchiolitis-obliterans\" class=\"medical medical_review\">&quot;Chronic lung transplant rejection: Bronchiolitis obliterans&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H31532913\"><span class=\"h1\">ANASTOMOTIC COMPLICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lung transplantation involves completion of three anastomoses: airway, pulmonary arterial, and pulmonary vein-to-left atrium. &#160;</p><p class=\"headingAnchor\" id=\"H16568541\"><span class=\"h2\">Airway anastomotic complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Airway anastomotic complications are discussed separately. (See <a href=\"topic.htm?path=airway-complications-after-lung-transplantation\" class=\"medical medical_review\">&quot;Airway complications after lung transplantation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16568548\"><span class=\"h2\">Vascular anastomotic complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Complications of the arterial and venous anastomoses are less frequently seen than airway anastomotic complications, but may have devastating effects. Vascular complications include stenosis, arterial kinking, and thrombus formation.</p><p class=\"headingAnchor\" id=\"H358248722\"><span class=\"h3\">Pulmonary artery stenosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary artery stenosis has been reported early and late after lung transplantation. Causes include excessive length of donor and recipient segments, distortion due to short donor length, technical narrowing, twisting of the anastomosis, and thrombus formation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/1\" class=\"abstract_t\">1</a>]. Symptoms such as shortness of breath and signs of pulmonary hypertension and right heart failure (eg, systemic hypotension, peripheral edema) suggest this diagnosis. Echocardiographic evidence of increased right ventricular pressure or right ventricular dysfunction may be present [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/2\" class=\"abstract_t\">2</a>]. Quantitative <span class=\"nowrap\">ventilation/perfusion</span> scanning shows blood flow that is unequally distributed between lungs after bilateral transplantation or disproportionate flow to the native lung after single lung transplantation. Computed tomography (CT) angiography and dynamic magnetic resonance (MR) angiography may also suggest the diagnosis; however, pulmonary angiography is usually necessary to confirm the diagnosis of pulmonary artery anastomotic stenosis (including documentation of a &gt;10 mmHg pressure gradient) and allows therapeutic measures such as balloon dilatation and stent placement [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/2-4\" class=\"abstract_t\">2-4</a>]. Surgical reconstruction is the final option for stenosis not amenable to other interventions [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H358248728\"><span class=\"h3\">Kinking of the pulmonary artery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Kinking of the pulmonary artery anastomosis has been described in case reports and has a similar presentation as pulmonary artery stenosis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/6,7\" class=\"abstract_t\">6,7</a>]. In one case, the kink was associated with decreased flow in the pulmonary vein, as assessed by transesophageal echocardiography [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/6\" class=\"abstract_t\">6</a>]. Percutaneous placement of a metallic stent was beneficial in both cases.</p><p class=\"headingAnchor\" id=\"H358248790\"><span class=\"h3\">Pulmonary vein thrombosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary venous thrombosis typically occurs in the early postoperative period. Thrombus formation at the pulmonary <span class=\"nowrap\">venous/left</span> atrial anastomotic suture line carries the risk of systemic embolization and cerebrovascular accident [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/8\" class=\"abstract_t\">8</a>]. Thrombi may also obstruct pulmonary venous outflow and cause severe pulmonary edema refractory to medical management [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/9,10\" class=\"abstract_t\">9,10</a>]. A prospective cohort study evaluated the incidence of pulmonary venous thrombosis in 87 consecutive lung transplant recipients, by performing transesophageal echocardiography within 48 hours of the transplant procedure [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/9\" class=\"abstract_t\">9</a>]. Thirteen (15 percent) had evidence of pulmonary <span class=\"nowrap\">venous/left</span> atrial clot. This subset of patients had a significantly increased risk of death (90-day mortality rate of 38 percent).</p><p>Clinical features include hypoxemia, decreased lung compliance, and diffuse radiographic opacities in the allograft, although some clinically-unsuspected pulmonary venous thrombi are detected by routine transesophageal echocardiography [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/11,12\" class=\"abstract_t\">11,12</a>]. Pulmonary artery and central venous pressures may be elevated. The differential diagnosis includes pulmonary vein stenosis, primary graft dysfunction, myocardial dysfunction, infection, and acute rejection [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/12\" class=\"abstract_t\">12</a>]. The diagnosis is typically made by transesophageal echocardiography. </p><p>There is no standardized approach to managing pulmonary vein thrombosis after lung transplantation. If the bleeding risk is not prohibitive, patients with symptomatic thrombi may benefit from systemic anticoagulation and, possibly, fibrinolytic therapy [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/12\" class=\"abstract_t\">12</a>]. Refractory hypoxemia <span class=\"nowrap\">and/or</span> hemodynamic instability may require emergent surgical thrombectomy, but outcomes are usually poor [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/13,14\" class=\"abstract_t\">13,14</a>]. On the other hand, two patients with small venous anastomotic thrombi and lack of accelerated flow velocity were monitored without specific therapy and the thrombi resolved spontaneously. </p><p class=\"headingAnchor\" id=\"H31533024\"><span class=\"h1\">PHRENIC NERVE AND DIAPHRAGMATIC DYSFUNCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The reported incidence of diaphragmatic paralysis following lung transplantation ranges from 3 to 9 percent in retrospective series [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/15-17\" class=\"abstract_t\">15-17</a>]. Phrenic nerve injury is more common following heart-lung transplantation; in one retrospective report, more than 40 percent of heart-lung transplant recipients developed this complication. (See <a href=\"topic.htm?path=heart-lung-transplantation#H16\" class=\"medical medical_review\">&quot;Heart-lung transplantation&quot;, section on 'Phrenic nerve dysfunction'</a>.)</p><p>The pathogenesis of phrenic nerve dysfunction is thought to include mechanical injury from intraoperative retraction of the sternum, manipulation of the pericardium, and mediastinal dissection, and also hypothermic injury when cold topical cardioplegia is used. No specific risk factors for phrenic nerve injury have been identified. </p><p>Diaphragm paralysis should be suspected when a patient has dyspnea, hypoxemia, hypoventilation, atelectasis, hemidiaphragm elevation on an upright chest radiograph, or difficulty weaning from the ventilator postoperatively [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/18\" class=\"abstract_t\">18</a>]. The diagnosis of unilateral diaphragmatic paralysis is usually made by fluoroscopic examination of the diaphragm, while bilateral paralysis may be strongly suspected based on the setting, bilateral elevation of the diaphragm, and supine and sitting spirometry. The diagnosis and management of diaphragm paralysis are discussed separately. (See <a href=\"topic.htm?path=causes-and-diagnosis-of-unilateral-diaphragmatic-paralysis-and-eventration-in-adults\" class=\"medical medical_review\">&quot;Causes and diagnosis of unilateral diaphragmatic paralysis and eventration in adults&quot;</a> and <a href=\"topic.htm?path=causes-and-diagnosis-of-bilateral-diaphragmatic-paralysis\" class=\"medical medical_review\">&quot;Causes and diagnosis of bilateral diaphragmatic paralysis&quot;</a> and <a href=\"topic.htm?path=treatment-of-diaphragmatic-paralysis\" class=\"medical medical_review\">&quot;Treatment of diaphragmatic paralysis&quot;</a>.)</p><p>Diaphragmatic dysfunction following lung transplantation results in longer hospital stays and longer duration of mechanical ventilation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/15,16,18-20\" class=\"abstract_t\">15,16,18-20</a>]. </p><p class=\"headingAnchor\" id=\"H31533163\"><span class=\"h1\">PLEURAL COMPLICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pleural complications are commonly seen after lung transplantation and include pneumothorax, bronchopleural fistula, pleural effusion, hemothorax, and chylothorax. These complications are discussed separately. (See <a href=\"topic.htm?path=pleural-complications-in-lung-transplantation\" class=\"medical medical_review\">&quot;Pleural complications in lung transplantation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H588583\"><span class=\"h1\">PRIMARY GRAFT DYSFUNCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary graft dysfunction (also known as primary graft failure, severe ischemia-reperfusion injury, or reimplantation response) is a severe, acute lung injury syndrome occurring in the first 72 hours after lung transplantation. It is characterized by diffuse radiographic opacities in the allograft and an increased alveolar-arterial oxygen gradient. Primary graft dysfunction is discussed separately. (See <a href=\"topic.htm?path=primary-lung-graft-dysfunction\" class=\"medical medical_review\">&quot;Primary lung graft dysfunction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H31533170\"><span class=\"h1\">VENOUS THROMBOEMBOLISM</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lung transplant recipients, like other patients undergoing major surgery, are at increased risk of venous thromboembolism (VTE). The reported incidence of pulmonary embolism ranges from 5 to 15 percent, while venous thrombosis was found in 20 to 45 percent when both upper and lower extremity thrombi were included [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/21-24\" class=\"abstract_t\">21-24</a>]. Risk factors for VTE among lung transplant recipients include older age, diabetes, pneumonia, and cardiopulmonary bypass [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/22-24\" class=\"abstract_t\">22-24</a>]. A randomized trial of <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a><span class=\"nowrap\">/<a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>/<a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a></span> versus <span class=\"nowrap\">tacrolimus/<a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>/prednisone</span> after lung transplantation suggested an increased risk of venous thromboembolism in those assigned to sirolimus (17 percent) compared with patients assigned to azathioprine (3 percent) [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/25\" class=\"abstract_t\">25</a>]. Upper extremity thrombosis is typically seen in association with central venous catheters [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/23\" class=\"abstract_t\">23</a>]. </p><p>Pulmonary artery reserve tends to be limited during the recovery phase; as a result, an embolus to the transplanted lung can have serious consequences [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/26\" class=\"abstract_t\">26</a>]. The presentation of thromboembolism is nonspecific, so a high index of suspicion is necessary when a transplant recipient presents with dyspnea, hypoxemia, or exercise desaturation. The diagnosis is typically obtained by computed tomography pulmonary angiography (CTP) or a ventilation-perfusion scan if radiographic contrast is contraindicated. The treatment is the same as for VTEs in general, although the risk of hemothorax may be greater. The diagnosis and treatment of VTE are discussed separately. (See <a href=\"topic.htm?path=overview-of-the-treatment-of-lower-extremity-deep-vein-thrombosis-dvt\" class=\"medical medical_review\">&quot;Overview of the treatment of lower extremity deep vein thrombosis (DVT)&quot;</a> and <a href=\"topic.htm?path=clinical-presentation-evaluation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-acute-pulmonary-embolism\" class=\"medical medical_review\">&quot;Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism&quot;</a> and <a href=\"topic.htm?path=treatment-prognosis-and-follow-up-of-acute-pulmonary-embolism-in-adults\" class=\"medical medical_review\">&quot;Treatment, prognosis, and follow-up of acute pulmonary embolism in adults&quot;</a> and <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-deep-vein-thrombosis-of-the-lower-extremity\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity&quot;</a>.)</p><p>Standard methods of VTE prophylaxis should be used, although they have not been prospectively evaluated in this population. (See <a href=\"topic.htm?path=prevention-of-venous-thromboembolic-disease-in-surgical-patients\" class=\"medical medical_review\">&quot;Prevention of venous thromboembolic disease in surgical patients&quot;</a>.)</p><p>Deep venous thrombosis associated with an indwelling central venous catheter in a lung transplant recipient is evaluated and managed with conventional approaches. In particular, there should be a high index of suspicion for the development of this complication in patients who required placement of large cannulas for extracorporeal membrane oxygenation (ECMO) for pre <span class=\"nowrap\">and/or</span> post-transplant support. (See <a href=\"topic.htm?path=catheter-related-upper-extremity-venous-thrombosis\" class=\"medical medical_review\">&quot;Catheter-related upper extremity venous thrombosis&quot;</a> and <a href=\"topic.htm?path=extracorporeal-membrane-oxygenation-ecmo-in-adults#H17\" class=\"medical medical_review\">&quot;Extracorporeal membrane oxygenation (ECMO) in adults&quot;, section on 'Thromboembolism'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MALIGNANCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Solid organ transplant recipients have a two-fold increased risk for developing malignancy [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/27\" class=\"abstract_t\">27</a>]. Among five-year lung transplant survivors, malignancy and noncutaneous malignancy have been reported in approximately 16 and 5 percent, respectively [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=development-of-malignancy-following-solid-organ-transplantation\" class=\"medical medical_review\">&quot;Development of malignancy following solid organ transplantation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H23355512\"><span class=\"h2\">Lung cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since the major indications for lung transplantation are diseases associated with an increased risk of lung cancer (eg, emphysema, idiopathic pulmonary fibrosis), single-lung recipients may be at higher risk than bilateral lung recipients for developing lung cancer, which is typically in the remaining native lung [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/29-33\" class=\"abstract_t\">29-33</a>]. In rare cases, the tumor represents recurrent disease in patients who were transplanted for bronchoalveolar carcinoma [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/34-37\" class=\"abstract_t\">34-37</a>]. A retrospective, multicenter study of 2168 consecutive lung transplant recipients (975 single-lung, 1211 bilateral-lung or heart-lung) from 1981 to 2001 reported a 2 percent incidence of bronchogenic carcinoma among single lung recipients [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/38\" class=\"abstract_t\">38</a>]. All cases developed in the native lung, and none were reported in patients who received bilateral or heart-lung transplants. In a separate study, lung cancer was identified in 12 of 520 lung recipients, and eleven were in the native lung [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/32\" class=\"abstract_t\">32</a>]. The rate of lung cancer in these studies does not appear to be greater than what has been observed in high-risk patients (smokers, chronic obstructive pulmonary disease <span class=\"nowrap\">[COPD]/idiopathic</span> pulmonary fibrosis [IPF] patients) in the general population [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/38-41\" class=\"abstract_t\">38-41</a>]. In a review of data from the US Scientific Registry of Transplant Recipients, lung transplant recipients were found to have 5.5 fold increased risk of lung cancer compared with the general population [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/27\" class=\"abstract_t\">27</a>].</p><p>Bronchogenic carcinoma arising in a lung allograft is rare, likely due to the careful donor selection process in which older age, significant history of tobacco use, and evidence of parenchymal lung disease identify organs that are unsuitable for transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/42\" class=\"abstract_t\">42</a>]. While the risk of developing lung cancer after lung transplantation relates largely to conventional risk factors, lung cancers that do arise appear to behave more aggressively under the influence of immunosuppression [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/31\" class=\"abstract_t\">31</a>]. In fact, tumor progression may be so rapid that it can be difficult to distinguish from an infectious process [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/29\" class=\"abstract_t\">29</a>]. Whether it is the loss of antitumor immune surveillance in the immunosuppressed host or specific properties of administered immunosuppressive drugs that promote tumor growth is uncertain [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/43,44\" class=\"abstract_t\">43,44</a>].</p><p>The evaluation of pulmonary nodules is discussed separately. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-the-incidental-pulmonary-nodule\" class=\"medical medical_review\">&quot;Diagnostic evaluation of the incidental pulmonary nodule&quot;</a> and <a href=\"topic.htm?path=differential-diagnosis-and-evaluation-of-multiple-pulmonary-nodules\" class=\"medical medical_review\">&quot;Differential diagnosis and evaluation of multiple pulmonary nodules&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Posttransplantation lymphoproliferative disorders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diverse lymphoproliferative diseases (including lymphoma) that arise after transplantation are referred to collectively as posttransplantation lymphoproliferative disorders (PTLD). They comprise a morphologically and clonally heterogeneous group of abnormal B-cell proliferative responses that have been associated with Epstein-Barr virus (EBV) infection, ranging from benign processes such as infectious mononucleosis-like illnesses and polyclonal hyperplasia to aggressive malignant lymphomas. PTLD occurs in approximately 5 percent of lung transplant recipients [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/45-47\" class=\"abstract_t\">45-47</a>]. Notably, the incidence of PTLD not associated with EBV infection is increasing with a recent study reporting that only about half of cases are now associated with EBV [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/48\" class=\"abstract_t\">48</a>]. Among all of the possible neoplasms that arise after lung transplantation, PTLD is second in frequency to nonmelanoma skin cancers. The clinical manifestations, diagnosis, and treatment of PTLD are discussed in detail separately. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-post-transplant-lymphoproliferative-disorders\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-post-transplant-lymphoproliferative-disorders\" class=\"medical medical_review\">&quot;Treatment and prevention of post-transplant lymphoproliferative disorders&quot;</a>.) </p><p>The following discussion is limited to issues specifically related to lung transplant recipients. The clinical presentation of PTLD may vary depending on timing after transplantation with intrathoracic or lung allograft involvement more commonly seen in cases presenting within the first year after transplantation while extrathoracic manifestations are more common with later presentations [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/37,49\" class=\"abstract_t\">37,49</a>]. PTLD in lung transplant recipients with intrathoracic involvement may present as single or multiple pulmonary nodules or masses, mediastinal adenopathy and pleural effusions [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/50-52\" class=\"abstract_t\">50-52</a>]. Diffuse lymphadenopathy and also gastrointestinal, cutaneous, and central nervous system involvement have also been reported [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/51,53-57\" class=\"abstract_t\">51,53-57</a>].</p><p>The risk of PTLD is markedly increased in transplant recipients who were Epstein-Barr virus (EBV)-seronegative before transplantation and then acquired a primary EBV infection in the posttransplant setting [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/58-61\" class=\"abstract_t\">58-61</a>]. Thus, the risk of PTLD is higher in children and young adults and is likely the reason for higher rates in lung transplant recipients with cystic fibrosis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/62\" class=\"abstract_t\">62</a>]. A greater intensity of immunosuppression is also associated with development of PTLD [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/58,60,63\" class=\"abstract_t\">58,60,63</a>]. The risk of PTLD remains uncertain with use of novel immunosuppressive agents and must be monitored carefully. In particular, as the off label use of <a href=\"topic.htm?path=belatacept-drug-information\" class=\"drug drug_general\">belatacept</a> (a selective T-lymphocyte costimulation blocker) is considered in lung transplantation, it must be recognized that an increased incidence of PTLD was seen in patients receiving belatacept instead of a calcineurin inhibitor (<a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>) in renal transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/64,65\" class=\"abstract_t\">64,65</a>]. (See <a href=\"topic.htm?path=maintenance-immunosuppressive-therapy-in-renal-transplantation-in-adults#H3989876796\" class=\"medical medical_review\">&quot;Maintenance immunosuppressive therapy in renal transplantation in adults&quot;, section on 'Patients who develop toxicity from calcineurin inhibitors'</a>.)</p><p>The initial treatment of PTLD after lung transplantation usually involves reduction in the intensity of maintenance immunosuppression. However, reduced immunosuppression increases the risk of developing allograft rejection [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/66\" class=\"abstract_t\">66</a>]. Beyond reduction in immunosuppression, therapy with the CD20 monoclonal antibody <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> is well tolerated and associated with response rates of 50 to 80 percent [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/51,55,67\" class=\"abstract_t\">51,55,67</a>]. Other options for treatment for patients who do not respond to rituximab are chemotherapy, radiation therapy, or a combination of these [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/51,68-70\" class=\"abstract_t\">51,68-70</a>]. Chemotherapy is typically reserved for refractory disease and EBV (-), CD20 (-) tumors. For bulky disease, especially in the GI tract, surgical intervention to reduce the risk of gut perforation may be considered. Novel immunomodulatory approaches using cytotoxic T lymphocytes from autologous or HLA-matched EBV positive donors are currently under investigation. The role of specific therapy is discussed in detail separately. (See <a href=\"topic.htm?path=treatment-and-prevention-of-post-transplant-lymphoproliferative-disorders\" class=\"medical medical_review\">&quot;Treatment and prevention of post-transplant lymphoproliferative disorders&quot;</a>.)</p><p>The role of prophylactic antiviral therapy in lung transplant recipients is not well-established, but many pediatric centers monitor EBV-seronegative recipients for evidence of viral activation. Prophylactic antiviral therapy at the time of early detection of primary EBV infection is discussed separately. (See <a href=\"topic.htm?path=treatment-and-prevention-of-post-transplant-lymphoproliferative-disorders#H15\" class=\"medical medical_review\">&quot;Treatment and prevention of post-transplant lymphoproliferative disorders&quot;, section on 'Prevention'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">RECURRENT PRIMARY DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of diseases have been reported to recur in the lung allograft, including:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sarcoidosis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/71-76\" class=\"abstract_t\">71-76</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymphangioleiomyomatosis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/77-79\" class=\"abstract_t\">77-79</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diffuse panbronchiolitis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/80\" class=\"abstract_t\">80</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary alveolar proteinosis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/81,82\" class=\"abstract_t\">81,82</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Desquamative interstitial pneumonia [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/83\" class=\"abstract_t\">83</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary Langerhans cell histiocytosis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/84-87\" class=\"abstract_t\">84-87</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bronchioloalveolar carcinoma [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/34,36,88\" class=\"abstract_t\">34,36,88</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic pulmonary hemosiderosis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/89,90\" class=\"abstract_t\">89,90</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Giant cell interstitial pneumonitis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/91\" class=\"abstract_t\">91</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alpha-1 antitrypsin deficiency [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/92,93\" class=\"abstract_t\">92,93</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary veno-occlusive disease [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/94\" class=\"abstract_t\">94</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polymyositis-associated interstitial lung disease [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/95\" class=\"abstract_t\">95</a>] </p><p/><p>Sarcoidosis in particular has had a high pathologic recurrence rate in some small series [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/96\" class=\"abstract_t\">96</a>]. It usually is discovered incidentally when noncaseating granulomas are noted on lung biopsy specimens, but these pathologic recurrences have not adversely affected outcome [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/70,72\" class=\"abstract_t\">70,72</a>]. </p><p>Because survival after lung transplantation is brief compared with the natural history of the underlying diseases, it would not be surprising for recurrence of other diseases to be described in the future among long-term surviving patients.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">GRAFT-VERSUS-HOST DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Graft-versus-host disease (GVHD) results from an attack by viable donor lymphocytes on recipient tissue and is manifested clinically by dysfunction of the skin, liver, gastrointestinal tract, and bone marrow (<a href=\"image.htm?imageKey=HEME%2F68233\" class=\"graphic graphic_table graphicRef68233 \">table 1</a>). GVHD is common following hematopoietic stem cell transplantation and is a rare complication of lung transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/97-99\" class=\"abstract_t\">97-99</a>]. (See <a href=\"topic.htm?path=pathogenesis-of-graft-versus-host-disease\" class=\"medical medical_review\">&quot;Pathogenesis of graft-versus-host disease&quot;</a>.)</p><p>Eight cases of GVHD following lung transplantation have been reported in the literature. In these cases, patients generally developed rapidly progressive cholestatic hepatitis, gastroenteritis, and dermatitis. Neutropenia is a common laboratory finding [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/97,100,101\" class=\"abstract_t\">97,100,101</a>]. The diagnosis is suggested based on clinical findings; however, severe drug reactions may result in a similar presentation. The diagnosis is confirmed by skin biopsy and by chimerism studies on peripheral blood, which quantify the percentage of circulating lymphocytes of donor and recipient origin. Although rare, GVHD in lung transplant recipients appears to have a very high mortality rate [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/97\" class=\"abstract_t\">97</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease&quot;</a> and <a href=\"topic.htm?path=prevention-of-acute-graft-versus-host-disease\" class=\"medical medical_review\">&quot;Prevention of acute graft-versus-host disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11855970\"><span class=\"h1\">DRUG-INDUCED PULMONARY TOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary toxicity due to immunosuppressive agents is an infrequent side-effect, but needs to be considered when a lung recipient receiving certain medications develops dyspnea, deteriorating oxygen saturation, and radiographic opacities. As an example, pulmonary toxicity is occasionally associated with use of mechanistic target of rapamycin (previously mammalian target of rapamycin, mTOR) inhibitors such as <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> or <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>. The pathogenesis is unknown and toxicity is not clearly dependent on serum levels [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/102,103\" class=\"abstract_t\">102,103</a>]. </p><p>Symptoms usually develop within six months of initiating mTOR therapy, although later presentations have been reported. Patients typically present with dry cough, progressive dyspnea, fatigue and weakness. Fever and hemoptysis may also be present [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/104\" class=\"abstract_t\">104</a>]. Radiographic abnormalities include bilateral interstitial opacities, alveolar consolidation and nodular opacities, which may persist for several months after drug cessation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/103,105,106\" class=\"abstract_t\">103,105,106</a>]. Lymphocytic alveolitis and, less commonly, alveolar hemorrhage are seen on analysis of bronchoalveolar lavage fluid. Histologic findings include organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia or BOOP), interstitial lymphocytic infiltrates, and sometimes alveolar hemorrhage [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/103,104,107\" class=\"abstract_t\">103,104,107</a>]. Since mTOR inhibitor-associated pulmonary toxicity is potentially reversible (especially if recognized early), it is important to consider it in the differential diagnosis for dyspnea and radiographic opacities in the lung transplant recipient [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/108\" class=\"abstract_t\">108</a>]. MTOR inhibitors may also be associated with increased risk of venous thromboembolism, thus the diagnosis of pulmonary embolism should be considered in patients with new onset dyspnea or hypoxemia [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/25\" class=\"abstract_t\">25</a>]. (See <a href=\"topic.htm?path=pulmonary-toxicity-associated-with-antineoplastic-therapy-molecularly-targeted-agents#H20\" class=\"medical medical_review\">&quot;Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents&quot;, section on 'Rapamycin and analogs'</a>.)</p><p class=\"headingAnchor\" id=\"H31533290\"><span class=\"h1\">EXTRAPULMONARY COMPLICATIONS</span></p><p class=\"headingAnchor\" id=\"H16568442\"><span class=\"h2\">Hyperammonemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Severe hyperammonemia has been reported as a rare and frequently fatal cause of coma in the early post-transplant period, affecting approximately 1 to 4 percent of lung transplant recipients [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/109-113\" class=\"abstract_t\">109-113</a>]. In addition to hepatic failure or urea cycle enzyme deficiencies, systemic infection with <em>Mycoplasma hominis </em>or <em>Ureaplasma</em> is a unique cause of hyperammonemia in lung transplant recipients. These microbes metabolize urea as an energy source and produce ammonia as a by-product. Treatment of hyperammonemia in these patients requires prompt initiation of antimicrobial therapy against these organisms. (See <a href=\"topic.htm?path=mycoplasma-hominis-and-ureaplasma-urealyticum-infections\" class=\"medical medical_review\">&quot;Mycoplasma hominis and Ureaplasma urealyticum infections&quot;</a> and <a href=\"topic.htm?path=hepatic-encephalopathy-in-adults-clinical-manifestations-and-diagnosis#H152815085\" class=\"medical medical_review\">&quot;Hepatic encephalopathy in adults: Clinical manifestations and diagnosis&quot;, section on 'Ammonia'</a>.)</p><p>The role of <em>Mycoplasma</em> and <em>Ureaplasma</em> in hyperammonemia was illustrated in the following studies. In a case report, a lung transplant recipient with fatal hyperammonemia was found to have <em>Mycoplasma hominis</em> infection in the blood and in various tissues (trachea, lung, small bowel, colon) [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/114\" class=\"abstract_t\">114</a>]. In a subsequent study, investigators found <em>Ureaplasma urealyticum</em> or<em> U. parvum</em> infection in lung transplant recipients with hyperammonemia syndrome, but did not detect these organisms in any of the 20 lung transplant recipients with normal ammonia concentrations [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/112\" class=\"abstract_t\">112</a>]. Administration of <em>Ureaplasma</em>-directed antimicrobials to the patients with hyperammonemia syndrome resulted in biochemical and clinical resolution of the disorder. It is not known why this condition is seen in the post-transplant setting.</p><p>Serum ammonia levels should be measured in lung transplant recipients presenting with clinical findings consistent with this condition (eg, unexplained lethargy, agitation, seizure). If ammonia levels are elevated, blood or plasma and bronchoalveolar (BAL) specimens should be tested for <em>Mycoplasma</em> and <em>Ureaplasma</em> by polymerase chain reaction (PCR) and culture. (See <a href=\"topic.htm?path=mycoplasma-hominis-and-ureaplasma-urealyticum-infections#H725159\" class=\"medical medical_review\">&quot;Mycoplasma hominis and Ureaplasma urealyticum infections&quot;, section on 'Diagnosis'</a>.)</p><p>While awaiting culture and PCR results, empiric therapy should be initiated against <em>Mycoplasma hominis</em> and <em>Ureaplasma</em> species. <em>M. hominis</em> is usually susceptible to tetracyclines; <em>Ureaplasma</em> species are generally susceptible to macrolides, fluoroquinolones, and tetracyclines. Combination antibiotic therapy is considered prudent given the risk of resistant organisms being present initially or developing during therapy [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/112\" class=\"abstract_t\">112</a>]. Antimicrobial therapy is described in greater detail separately. (See <a href=\"topic.htm?path=mycoplasma-hominis-and-ureaplasma-urealyticum-infections#H1714648296\" class=\"medical medical_review\">&quot;Mycoplasma hominis and Ureaplasma urealyticum infections&quot;, section on 'Ureaplasma spp'</a>.)</p><p>Additional interventions such as elimination of exogenous nitrogen sources from feedings, hemodialysis to clear ammonia from the blood stream, and administration of intravenous <a href=\"topic.htm?path=sodium-benzoate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium benzoate</a> and sodium phenylacetate to serve as alternatives to urea for the excretion of nitrogenous wastes may also be of benefit [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/115,116\" class=\"abstract_t\">115,116</a>]. In one patient, an intracerebral drain was placed to manage brain edema [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/115\" class=\"abstract_t\">115</a>]. </p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Cardiac complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several cardiac complications may develop after lung transplantation. Early recognition and prompt treatment are essential to improving patient outcomes.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Atrial dysrhythmias</strong> &mdash; Atrial dysrhythmias are quite common after cardiothoracic procedures, including lung transplantation. The incidence of atrial arrhythmias (most commonly atrial fibrillation) early in the postoperative period ranges from 25 to 35 percent [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/117-120\" class=\"abstract_t\">117-120</a>]. Risk factors include older age, male sex, left atrial enlargement, prior atrial fibrillation, idiopathic pulmonary fibrosis, regurgitant valvulopathy, coronary artery disease, diastolic dysfunction, and the use of cardiopulmonary bypass [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/117-119,121,122\" class=\"abstract_t\">117-119,121,122</a>].</p><p/><p class=\"bulletIndent1\">The surgical anastomosis between the donor left atrial <span class=\"nowrap\">cuff/pulmonary</span> veins and recipient left atrium seems to be an important site for the development of the macro-reentry circuit of atrial flutter [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/123\" class=\"abstract_t\">123</a>]. Atrial dysrhythmias usually respond to conventional therapies such as antiarrhythmic medications and cardioversion. Nevertheless, this complication is associated with prolonged hospital stays and increased mortality [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/118\" class=\"abstract_t\">118</a>]. Medical therapy can often be stopped within two to three months after transplantation with low risk for recurrence. Studies have shown a low risk of atrial fibrillation late after lung transplantation, when atrial flutter and atrial tachycardias were more common [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/118,124\" class=\"abstract_t\">118,124</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hemodynamic instability</strong> &mdash; Hypotension is quite common in the immediate post-transplant period and usually responds well to judicious administration of volume, vasopressors, and inotropes. Intraoperative coronary artery air embolism, cardiac manipulation during the procedure, postoperative coronary artery embolism of small thrombi from the left atrial pulmonary venous anastomosis, or infarction from pre-existing coronary artery disease can cause myocardial injury, but clinically significant myocardial injury with ventricular dysfunction is uncommon because most of these complications are preventable. On the other hand, a pretransplant diagnosis of severe pulmonary arterial hypertension is associated with increased risk of life threatening hemodynamic instability. Severe right ventricular dysfunction, requirement for cardiopulmonary bypass with attendant risk of hemorrhage, and increased incidence of early graft failure contribute to this risk [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/125\" class=\"abstract_t\">125</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Coronary artery disease</strong> &#9472; Over the long-term, risk factors for coronary artery disease develop in many lung transplant recipients [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/28\" class=\"abstract_t\">28</a>]. Among five-year survivors in the Registry of the International Society for Heart and Lung Transplantation, the prevalence of risk factors was very high: systemic hypertension, 82 percent; hyperlipidemia, 59 percent; renal insufficiency, 55 percent with 3 percent requiring dialysis; and diabetes mellitus, 40 percent. In a single-center, retrospective study of 126 recipients without hypertension, hypercholesterolemia, or diabetes mellitus before transplantation, at least one cardiovascular risk factor had developed in 90 percent of the recipients by three years after transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/126\" class=\"abstract_t\">126</a>]. Most of these risk factors are, directly or indirectly, related to the post-transplantation immunosuppressive medications. Thus, to a certain extent, these risk factors are unavoidable, but they should be controlled as well as possible with the standard modalities of diet, exercise, and drug therapy. Perhaps surprisingly, a study comparing lung transplant recipients with mild asymptomatic coronary artery disease (who were not previously revascularized or revascularized during lung transplantation) had a 6 percent risk of progression requiring intervention post-transplant [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/127\" class=\"abstract_t\">127</a>]. Age, atrial fibrillation, and a diagnosis of IPF were independent predictors of postoperative cardiac events.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pericarditis</strong> &ndash; A few case reports have described constrictive pericarditis developing in bilateral lung transplant recipients six months to nine years following transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/128-131\" class=\"abstract_t\">128-131</a>]. Patients typically present with dyspnea, orthopnea, and lower extremity edema. Infectious and malignant causes of pericarditis must be sought and excluded [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/131-134\" class=\"abstract_t\">131-134</a>]. Treatment is usually pericardiectomy [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/128-131\" class=\"abstract_t\">128-131</a>]. The diagnosis and management of constrictive pericarditis are discussed separately. (See <a href=\"topic.htm?path=constrictive-pericarditis\" class=\"medical medical_review\">&quot;Constrictive pericarditis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H11855898\"><span class=\"h2\">Diabetes mellitus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>New onset diabetes mellitus occurs in approximately 25 to 30 percent of lung transplant recipients followed for one year and 40 percent at five years [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/28,126,135,136\" class=\"abstract_t\">28,126,135,136</a>]. Almost half of all transplant recipients have diabetes mellitus at one to two years after lung transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/137\" class=\"abstract_t\">137</a>]. Risk factors leading to development of diabetes mellitus include glucose levels after oral glucose tolerance testing before transplant, glucocorticoid and calcineurin use, older age, and obesity (body mass index &gt;30) [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/138\" class=\"abstract_t\">138</a>]. Patients on <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> have a greater likelihood of developing diabetes than those on <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, although glucose intolerance is not considered a reason to switch from tacrolimus to cyclosporine. The presence of diabetes mellitus is associated with an increased risk of death in lung transplant recipients [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/137,139-141\" class=\"abstract_t\">137,139-141</a>]. International consensus guidelines for the management of new onset diabetes after transplant were published in 2003 and were based on the observation that poorly controlled DM was associated with reduced graft function after kidney transplantation. Regular monitoring of fasting blood glucose has been recommended in more recent reports, weekly for the first month, every three months for the first post-transplant year, and then annually. Periodic screening with HgB A1c measurement is an alternative approach (every three to six months) that may be more sensitive [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/142\" class=\"abstract_t\">142</a>]. (See <a href=\"topic.htm?path=new-onset-diabetes-after-transplant-nodat-in-renal-transplant-recipients\" class=\"medical medical_review\">&quot;New-onset diabetes after transplant (NODAT) in renal transplant recipients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H31532894\"><span class=\"h2\">Renal insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute renal failure (ARF) is commonly seen after lung transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/143-146\" class=\"abstract_t\">143-146</a>]. In a retrospective analysis, 424 of 657 lung transplant recipients had at least one episode of acute kidney injury (AKI) in the first two weeks following transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/143\" class=\"abstract_t\">143</a>]. In a cohort from the University of Alberta, 69 percent had AKI early after lung transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/147\" class=\"abstract_t\">147</a>]. In a separate study, 166 out of 296 (56 percent) consecutive transplant recipients developed acute renal insufficiency, although only 8 percent needed dialysis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/144\" class=\"abstract_t\">144</a>]. ARF requiring renal replacement therapy (RRT) was associated with an increased risk for early mortality. Independent predictors of post-transplant severe ARF were preoperative diagnoses of pulmonary hypertension and idiopathic pulmonary fibrosis, reduced baseline glomerular filtration rate (GFR), mechanical ventilation &gt;24 hours and use of intravenous amphotericin B. A study of over 12,000 patients who underwent lung transplantation in the United States between 2001 and 2011 showed that the risk of RRT for acute renal failure was 6 percent [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/148\" class=\"abstract_t\">148</a>]. Preoperative kidney function was an important predictor of RRT, with a 42 percent increase in odds for a preoperative GFR of 60 to 90 (p = 0.001) and a more than doubling in odds of RRT for GFR less than 60 (p&lt;0.001). The presence of AKI requiring RRT is a risk factor for mortality [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/147,148\" class=\"abstract_t\">147,148</a>].</p><p>Chronic kidney disease (CKD) has been reported in 5 percent of lung recipients within three years of transplantation and approximately 15 percent at six years [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/149\" class=\"abstract_t\">149</a>]; higher estimates (68 percent at five years) are seen using a lower threshold to define CKD (GFR &lt;60 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>). In the International Society of Heart Lung Transplant Registry, a creatinine &gt;2.5 <span class=\"nowrap\">mg/dL</span> was noted in 15 percent of lung transplant recipients at five years post-transplant [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/28\" class=\"abstract_t\">28</a>]. Chronic renal failure is also associated with increased mortality [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/149,150\" class=\"abstract_t\">149,150</a>]. Depending on the study and patient population, implicated risk factors for chronic renal insufficiency include age, a history of smoking [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/150,151\" class=\"abstract_t\">150,151</a>], gender, early ARF, use of calcineurin inhibitors and other nephrotoxic drugs, hypertension, sarcoidosis, and diabetes [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/152-154\" class=\"abstract_t\">152-154</a>]. Equations for estimation of GFR are the best predictors of the risk of CKD after lung transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/154,155\" class=\"abstract_t\">154,155</a>]. Risk factors, prevention, and treatment of post-transplant nephrotoxicity are discussed separately. (See <a href=\"topic.htm?path=assessment-of-kidney-function#H20659769\" class=\"medical medical_review\">&quot;Assessment of kidney function&quot;, section on 'Estimation equations'</a> and <a href=\"topic.htm?path=cyclosporine-and-tacrolimus-nephrotoxicity#H5\" class=\"medical medical_review\">&quot;Cyclosporine and tacrolimus nephrotoxicity&quot;, section on 'Incidence'</a> and <a href=\"topic.htm?path=renal-function-and-nonrenal-solid-organ-transplantation#H12\" class=\"medical medical_review\">&quot;Renal function and nonrenal solid organ transplantation&quot;, section on 'Lung transplantation'</a> and <a href=\"topic.htm?path=renal-function-and-nonrenal-solid-organ-transplantation#H16\" class=\"medical medical_review\">&quot;Renal function and nonrenal solid organ transplantation&quot;, section on 'Prevention and treatment strategies'</a>.)</p><p class=\"headingAnchor\" id=\"H590353\"><span class=\"h2\">Pneumatosis intestinalis and pneumoperitoneum</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pneumatosis intestinalis (PI) refers to the presence of gas within the wall of the small or large intestine. In a series of 321 bilateral lung transplants, pneumatosis intestinalis (PI) or pneumoperitoneum were identified on imaging studies in seven asymptomatic patients [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/156\" class=\"abstract_t\">156</a>]. In these patients, PI was manifest by a linear and cystic appearance involving only the colon. Three of the six patients with PI, also had pneumoperitoneum. No definite cause for these findings was identified and the radiographic findings resolved spontaneously at a mean of 24 days. (See <a href=\"topic.htm?path=pneumatosis-intestinalis\" class=\"medical medical_review\">&quot;Pneumatosis intestinalis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21179952\"><span class=\"h2\">Neurologic complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neurologic complications are common after lung transplant, affecting 92 percent of patients in one cohort [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/157\" class=\"abstract_t\">157</a>]. In this cohort, older age was a significant predictor of neurologic complications. Encephalopathy was the most common complication and most often occurred in the early postoperative period.</p><p>Stroke has been reported to occur in approximately 5 to 10 percent of lung recipients [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/157-159\" class=\"abstract_t\">157-159</a>]. In addition to the well-recognized atherothrombotic mechanisms of stroke, two embolic mechanisms unique to this patient population must also be considered. Failure to fully de-gas the pulmonary vascular tree and cardiac chambers after completion of the vascular anastomosis can lead to air embolism immediately upon lung reperfusion or in the early postoperative period. In addition, formation of thrombus at the left atrial anastomotic site can result in embolic stroke days to weeks after transplantation. (See <a href=\"#H16568548\" class=\"local\">'Vascular anastomotic complications'</a> above.) </p><p>Clinical and radiographic findings consistent with multiple areas of brain infarction should prompt performance of transesophageal echocardiography. If thrombus is documented, systemic anticoagulation should be initiated in the absence of other contraindications. (See <a href=\"#H358248790\" class=\"local\">'Pulmonary vein thrombosis'</a> above.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Other complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lung transplant recipients may develop a panoply of other medical and surgical problems. Most of these are not unique to lung transplantation, but instead are side effects of the immunosuppressive medications or general medical problems that are aggravated by the posttransplantation regimen [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/43,160\" class=\"abstract_t\">43,160</a>]. </p><p>Prominent problems include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Osteoporosis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/160-164\" class=\"abstract_t\">160-164</a>]. (See <a href=\"topic.htm?path=osteoporosis-after-solid-organ-or-stem-cell-transplantation\" class=\"medical medical_review\">&quot;Osteoporosis after solid organ or stem cell transplantation&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Obesity [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/165-167\" class=\"abstract_t\">165-167</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anemia [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/63\" class=\"abstract_t\">63</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gastroparesis and gastroesophageal reflux disease (GERD) [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/168\" class=\"abstract_t\">168</a>]. (See <a href=\"topic.htm?path=physiologic-changes-following-lung-transplantation#H7\" class=\"medical medical_review\">&quot;Physiologic changes following lung transplantation&quot;, section on 'Oropharyngeal dysphagia, gastroesophageal reflux, and gastroparesis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypercholesterolemia and hypertriglyceridemia [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/28,126\" class=\"abstract_t\">28,126</a>]. Hyperlipidemia is reported in 59 percent of lung transplant recipients within five years after transplant [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=lipid-abnormalities-after-renal-transplantation\" class=\"medical medical_review\">&quot;Lipid abnormalities after renal transplantation&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cholecystitis, diverticulitis, gastrointestinal perforation, pancreatitis [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/169,170\" class=\"abstract_t\">169,170</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Distal intestinal obstruction syndrome in patients with cystic fibrosis &ndash; Distal intestinal obstruction syndrome (DIOS), formerly known as &quot;meconium ileus equivalent,&rdquo; is characterized by an acute complete or partial obstruction of the ileocecum by intestinal contents and may occur with increased frequency following lung transplantation [<a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/171,172\" class=\"abstract_t\">171,172</a>]. (See <a href=\"topic.htm?path=cystic-fibrosis-overview-of-gastrointestinal-disease#H10\" class=\"medical medical_review\">&quot;Cystic fibrosis: Overview of gastrointestinal disease&quot;, section on 'Distal intestinal obstruction syndrome (DIOS)'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Weakness of respiratory and limb muscles. (See <a href=\"topic.htm?path=physiologic-changes-following-lung-transplantation#H8\" class=\"medical medical_review\">&quot;Physiologic changes following lung transplantation&quot;, section on 'Respiratory and skeletal muscle function'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H16568307\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lung transplant related complications involving acute and chronic lung transplant rejection, airway anastomotic problems, pleural complications, and primary graft dysfunction are discussed separately. (See <a href=\"topic.htm?path=evaluation-and-treatment-of-acute-lung-transplant-rejection\" class=\"medical medical_review\">&quot;Evaluation and treatment of acute lung transplant rejection&quot;</a> and <a href=\"topic.htm?path=evaluation-and-treatment-of-antibody-mediated-lung-transplant-rejection\" class=\"medical medical_review\">&quot;Evaluation and treatment of antibody-mediated lung transplant rejection&quot;</a> and <a href=\"topic.htm?path=chronic-lung-transplant-rejection-bronchiolitis-obliterans\" class=\"medical medical_review\">&quot;Chronic lung transplant rejection: Bronchiolitis obliterans&quot;</a> and <a href=\"topic.htm?path=airway-complications-after-lung-transplantation\" class=\"medical medical_review\">&quot;Airway complications after lung transplantation&quot;</a> and <a href=\"topic.htm?path=pleural-complications-in-lung-transplantation\" class=\"medical medical_review\">&quot;Pleural complications in lung transplantation&quot;</a> and <a href=\"topic.htm?path=primary-lung-graft-dysfunction\" class=\"medical medical_review\">&quot;Primary lung graft dysfunction&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complications of the pulmonary artery and pulmonary <span class=\"nowrap\">vein/left</span> atrium anastomoses, such as thrombus formation, stenosis, and arterial kinking, occur less frequently than airway anastomotic complications, but may have devastating effects. (See <a href=\"#H16568548\" class=\"local\">'Vascular anastomotic complications'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diaphragmatic dysfunction due to phrenic nerve injury complicates approximately 3 to 9 percent of lung transplantations. Diaphragm paralysis should be suspected in patients with postoperative dyspnea, hypoxemia, hypoventilation, atelectasis, unilateral or bilateral diaphragm elevation on an upright chest radiograph, <span class=\"nowrap\">and/or</span> difficulty weaning from the ventilator postoperatively. (See <a href=\"#H31533024\" class=\"local\">'Phrenic nerve and diaphragmatic dysfunction'</a> above and <a href=\"topic.htm?path=causes-and-diagnosis-of-unilateral-diaphragmatic-paralysis-and-eventration-in-adults\" class=\"medical medical_review\">&quot;Causes and diagnosis of unilateral diaphragmatic paralysis and eventration in adults&quot;</a> and <a href=\"topic.htm?path=causes-and-diagnosis-of-bilateral-diaphragmatic-paralysis\" class=\"medical medical_review\">&quot;Causes and diagnosis of bilateral diaphragmatic paralysis&quot;</a> and <a href=\"topic.htm?path=treatment-of-diaphragmatic-paralysis\" class=\"medical medical_review\">&quot;Treatment of diaphragmatic paralysis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lung transplant recipients are at increased risk of venous thromboembolism (VTE). A high index of suspicion for VTE is necessary when a transplant recipient presents with dyspnea, hypoxemia, or exercise desaturation. (See <a href=\"#H31533170\" class=\"local\">'Venous thromboembolism'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lung transplant recipients have an increased risk for developing malignancy. As lung diseases associated with cigarette smoking are frequent indications for lung transplant, it is not surprising that lung cancer occurs in the native lung in approximately 2 percent of single lung recipients. Overall, lung transplant recipients have a 5.5 fold increased risk of lung cancer compared with the general population. (See <a href=\"#H2\" class=\"local\">'Malignancy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The risk of PTLD in lung transplant recipients is approximately 5 percent, but is substantially higher in transplant recipients who are Epstein-Barr virus (EBV)-seronegative before transplantation and acquire a primary EBV infection in the posttransplant setting. Notably, the incidence of PTLD not associated with EBV infection is increasing. The clinical presentation of PTLD may vary depending on timing after transplantation with intrathoracic or lung allograft involvement more commonly seen in cases presenting within the first year after transplantation while extrathoracic manifestations are more common with later presentations. (See <a href=\"#H3\" class=\"local\">'Posttransplantation lymphoproliferative disorders'</a> above and <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-post-transplant-lymphoproliferative-disorders\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-post-transplant-lymphoproliferative-disorders\" class=\"medical medical_review\">&quot;Treatment and prevention of post-transplant lymphoproliferative disorders&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A number of diseases have been reported to recur in the lung allograft, including sarcoidosis, lymphangioleiomyomatosis, diffuse panbronchiolitis, pulmonary alveolar proteinosis, desquamative interstitial pneumonia, pulmonary Langerhans cell histiocytosis, bronchioloalveolar carcinoma, and idiopathic pulmonary hemosiderosis. (See <a href=\"#H5\" class=\"local\">'Recurrent primary disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Graft-versus-host disease (GVHD) results from an attack by viable donor lymphocytes from the lung allograft on recipient tissues (eg, skin, gastrointestinal tract, liver, bone marrow) and is a rare complication of lung transplantation. (See <a href=\"#H6\" class=\"local\">'Graft-versus-host disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary toxicity due to immunosuppressive agents (eg, <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a>) is an infrequent adverse effect following lung transplantation, but needs to be considered when a lung recipient develops dyspnea, deteriorating oxygen saturation, and radiographic opacities. (See <a href=\"#H11855970\" class=\"local\">'Drug-induced pulmonary toxicity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lung transplant recipients are at risk for other complications due to adverse effects of immunosuppressive medications or their underlying disease, including hyperammonemia, atrial dysrhythmias, hemodynamic instability, coronary artery disease, diabetes mellitus, renal insufficiency, pneumatosis intestinalis, and stroke. (See <a href=\"#H31533290\" class=\"local\">'Extrapulmonary complications'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/1\" class=\"nounderline abstract_t\">Anaya-Ayala JE, Loebe M, Davies MG. Endovascular management of early lung transplant-related anastomotic pulmonary artery stenosis. J Vasc Interv Radiol 2015; 26:878.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/2\" class=\"nounderline abstract_t\">Waurick PE, Kleber FX, Ewert R, et al. Pulmonary artery stenosis 5 years after single lung transplantation in primary pulmonary hypertension. J Heart Lung Transplant 1999; 18:1243.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/3\" class=\"nounderline abstract_t\">Banerjee SK, Santhanakrishnan K, Shapiro L, et al. Successful stenting of anastomotic stenosis of the left pulmonary artery after single lung transplantation. Eur Respir Rev 2011; 20:59.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/4\" class=\"nounderline abstract_t\">Lumsden AB, Anaya-Ayala JE, Birnbaum I, et al. Robot-assisted stenting of a high-grade anastomotic pulmonary artery stenosis following single lung transplantation. J Endovasc Ther 2010; 17:612.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/5\" class=\"nounderline abstract_t\">Soriano CM, Gaine SP, Conte JV, et al. Anastomotic pulmonary hypertension after lung transplantation for primary pulmonary hypertension: report of surgical correction. Chest 1999; 116:564.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/6\" class=\"nounderline abstract_t\">Miyaji K, Nakamura K, Maruo T, et al. Effect of a kink in unilateral pulmonary artery anastomosis on velocities of blood flow through bilateral pulmonary vein anastomoses in living-donor lobar lung transplantation. J Am Soc Echocardiogr 2004; 17:998.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/7\" class=\"nounderline abstract_t\">Chen F, Tazaki J, Shibata T, et al. Stent angioplasty for a kink in the pulmonary artery anastomosis soon after living-donor lobar lung transplantation. Ann Thorac Surg 2011; 92:e105.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/8\" class=\"nounderline abstract_t\">Uhlmann EJ, Dunitz JM, Fiol ME. Pulmonary vein thrombosis after lung transplantation presenting as stroke. J Heart Lung Transplant 2009; 28:209.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/9\" class=\"nounderline abstract_t\">Schulman LL, Anandarangam T, Leibowitz DW, et al. Four-year prospective study of pulmonary venous thrombosis after lung transplantation. J Am Soc Echocardiogr 2001; 14:806.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/10\" class=\"nounderline abstract_t\">Leibowitz DW, Smith CR, Michler RE, et al. Incidence of pulmonary vein complications after lung transplantation: a prospective transesophageal echocardiographic study. J Am Coll Cardiol 1994; 24:671.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/11\" class=\"nounderline abstract_t\">McIlroy DR, Sesto AC, Buckland MR. Pulmonary vein thrombosis, lung transplantation, and intraoperative transesophageal echocardiography. J Cardiothorac Vasc Anesth 2006; 20:712.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/12\" class=\"nounderline abstract_t\">Gonz&aacute;lez-Fern&aacute;ndez C, Gonz&aacute;lez-Castro A, Rodr&iacute;guez-Borreg&aacute;n JC, et al. Pulmonary venous obstruction after lung transplantation. Diagnostic advantages of transesophageal echocardiography. Clin Transplant 2009; 23:975.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/13\" class=\"nounderline abstract_t\">Shah AS, Michler RE, Downey RJ, et al. Management strategies for pulmonary vein thrombosis following single lung transplantation. J Card Surg 1995; 10:169.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/14\" class=\"nounderline abstract_t\">Nagahiro I, Horton M, Wilson M, et al. Pulmonary vein thrombosis treated successfully by thrombectomy after bilateral sequential lung transplantation: report of a case. Surg Today 2003; 33:282.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/15\" class=\"nounderline abstract_t\">Maziak DE, Maurer JR, Kesten S. Diaphragmatic paralysis: a complication of lung transplantation. Ann Thorac Surg 1996; 61:170.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/16\" class=\"nounderline abstract_t\">Ferdinande P, Bruyninckx F, Van Raemdonck D, et al. Phrenic nerve dysfunction after heart-lung and lung transplantation. J Heart Lung Transplant 2004; 23:105.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/17\" class=\"nounderline abstract_t\">Sano Y, Oto T, Toyooka S, et al. [Phrenic nerve paralysis following lung transplantation]. Kyobu Geka 2007; 60:993.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/18\" class=\"nounderline abstract_t\">Berk Y, van der Bij W, Erasmus ME, Wijkstra PJ. Non-invasive ventilation in phrenic nerve dysfunction after lung transplantation: an attractive option. J Heart Lung Transplant 2006; 25:1483.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/19\" class=\"nounderline abstract_t\">Sheridan PH Jr, Cheriyan A, Doud J, et al. Incidence of phrenic neuropathy after isolated lung transplantation. The Loyola University Lung Transplant Group. J Heart Lung Transplant 1995; 14:684.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/20\" class=\"nounderline abstract_t\">Shihata M, Mullen JC. Bilateral diaphragmatic plication in the setting of bilateral sequential lung transplantation. Ann Thorac Surg 2007; 83:1201.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/21\" class=\"nounderline abstract_t\">Izbicki G, Bairey O, Shitrit D, et al. Increased thromboembolic events after lung transplantation. Chest 2006; 129:412.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/22\" class=\"nounderline abstract_t\">Yegen HA, Lederer DJ, Barr RG, et al. Risk factors for venous thromboembolism after lung transplantation. Chest 2007; 132:547.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/23\" class=\"nounderline abstract_t\">Kahan ES, Petersen G, Gaughan JP, Criner GJ. High incidence of venous thromboembolic events in lung transplant recipients. J Heart Lung Transplant 2007; 26:339.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/24\" class=\"nounderline abstract_t\">Evans CF, Iacono AT, Sanchez PG, et al. Venous Thromboembolic Complications of Lung Transplantation: A Contemporary Single-Institution Review. Ann Thorac Surg 2015; 100:2033.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/25\" class=\"nounderline abstract_t\">Ahya VN, McShane PJ, Baz MA, et al. Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation. J Heart Lung Transplant 2011; 30:175.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/26\" class=\"nounderline abstract_t\">Noda S, Sundt TM 3rd, Lynch JP, et al. Pulmonary embolectomy after single-lung transplantation. Ann Thorac Surg 1997; 64:1459.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/27\" class=\"nounderline abstract_t\">Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306:1891.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/28\" class=\"nounderline abstract_t\">Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34:1264.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/29\" class=\"nounderline abstract_t\">Arcasoy SM, Hersh C, Christie JD, et al. Bronchogenic carcinoma complicating lung transplantation. J Heart Lung Transplant 2001; 20:1044.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/30\" class=\"nounderline abstract_t\">Yserbyt J, Verleden GM, Dupont LJ, et al. Bronchial carcinoma after lung transplantation: a single-center experience. J Heart Lung Transplant 2012; 31:585.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/31\" class=\"nounderline abstract_t\">Grewal AS, Padera RF, Boukedes S, et al. Prevalence and outcome of lung cancer in lung transplant recipients. Respir Med 2015; 109:427.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/32\" class=\"nounderline abstract_t\">Minai OA, Shah S, Mazzone P, et al. Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J Thorac Oncol 2008; 3:1404.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/33\" class=\"nounderline abstract_t\">Raviv Y, Shitrit D, Amital A, et al. Lung cancer in lung transplant recipients: experience of a tertiary hospital and literature review. Lung Cancer 2011; 74:280.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/34\" class=\"nounderline abstract_t\">Garver RI Jr, Zorn GL, Wu X, et al. Recurrence of bronchioloalveolar carcinoma in transplanted lungs. N Engl J Med 1999; 340:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/35\" class=\"nounderline abstract_t\">de Perrot M, Fischer S, Waddell TK, et al. Management of lung transplant recipients with bronchogenic carcinoma in the native lung. J Heart Lung Transplant 2003; 22:87.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/36\" class=\"nounderline abstract_t\">de Perrot M, Chernenko S, Waddell TK, et al. Role of lung transplantation in the treatment of bronchogenic carcinomas for patients with end-stage pulmonary disease. J Clin Oncol 2004; 22:4351.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/37\" class=\"nounderline abstract_t\">Ahmad U, Wang Z, Bryant AS, et al. Outcomes for lung transplantation for lung cancer in the United Network for Organ Sharing Registry. Ann Thorac Surg 2012; 94:935.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/38\" class=\"nounderline abstract_t\">Collins J, Kazerooni EA, Lacomis J, et al. Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics, and imaging findings. Radiology 2002; 224:131.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/39\" class=\"nounderline abstract_t\">Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354:99.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/40\" class=\"nounderline abstract_t\">Ma Y, Seneviratne CK, Koss M. Idiopathic pulmonary fibrosis and malignancy. Curr Opin Pulm Med 2001; 7:278.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/41\" class=\"nounderline abstract_t\">Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161:5.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/42\" class=\"nounderline abstract_t\">Orens JB, Boehler A, de Perrot M, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003; 22:1183.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/43\" class=\"nounderline abstract_t\">Kotloff RM, Ahya VN. Medical complications of lung transplantation. Eur Respir J 2004; 23:334.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/44\" class=\"nounderline abstract_t\">Suthanthiran M, Hojo M, Maluccio M, et al. Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy. Trans Am Clin Climatol Assoc 2009; 120:369.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/45\" class=\"nounderline abstract_t\">Wudhikarn K, Holman CJ, Linan M, et al. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota. Clin Transplant 2011; 25:705.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/46\" class=\"nounderline abstract_t\">Kremer BE, Reshef R, Misleh JG, et al. Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases. J Heart Lung Transplant 2012; 31:296.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/47\" class=\"nounderline abstract_t\">Thomas de Montpr&eacute;ville V, Le Pavec J, Le Roy Ladurie F, et al. Lymphoproliferative Disorders after Lung Transplantation: Clinicopathological Characterization of 16 Cases with Identification of Very-Late-Onset Forms. Respiration 2015; 90:451.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/48\" class=\"nounderline abstract_t\">Luskin MR, Heil DS, Tan KS, et al. The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder. Am J Transplant 2015; 15:2665.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/49\" class=\"nounderline abstract_t\">Bakker NA, van Imhoff GW, Verschuuren EA, et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005; 19:327.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/50\" class=\"nounderline abstract_t\">Rappaport DC, Chamberlain DW, Shepherd FA, Hutcheon MA. Lymphoproliferative disorders after lung transplantation: imaging features. Radiology 1998; 206:519.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/51\" class=\"nounderline abstract_t\">Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124:1242.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/52\" class=\"nounderline abstract_t\">Opelz G, D&ouml;hler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4:222.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/53\" class=\"nounderline abstract_t\">Heller T, Drachenberg CB, Orens JB, Fantry GT. Primary posttransplant lymphoproliferative disorder of the gallbladder in a lung transplant patient presenting with acute cholecystitis. Transplantation 2000; 69:668.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/54\" class=\"nounderline abstract_t\">Herrmann BW, Sweet SC, Molter DW. Sinonasal posttransplant lymphoproliferative disorder in pediatric lung transplant patients. Otolaryngol Head Neck Surg 2005; 133:38.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/55\" class=\"nounderline abstract_t\">Loren AW, Tsai DE. Post-transplant lymphoproliferative disorder. Clin Chest Med 2005; 26:631.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/56\" class=\"nounderline abstract_t\">Bakker NA, van Dijk JM, Slart RH, et al. Extradural thoracic spinal cord compression: unusual initial presentation of post-transplant lymphoproliferative disorder. J Heart Lung Transplant 2008; 27:1165.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/57\" class=\"nounderline abstract_t\">Gifford G, Fay K, Jabbour A, Ma DD. Primary central nervous system posttransplantation lymphoproliferative disorder after heart and lung transplantation. Intern Med J 2015; 45:583.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/58\" class=\"nounderline abstract_t\">Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-na&iuml;ve lung transplant recipient. Am J Respir Crit Care Med 1996; 154:1712.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/59\" class=\"nounderline abstract_t\">Wigle DA, Chaparro C, Humar A, et al. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001; 72:1783.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/60\" class=\"nounderline abstract_t\">Verschuuren E, van der Bij W, de Boer W, et al. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease. J Med Virol 2003; 69:258.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/61\" class=\"nounderline abstract_t\">Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14:214.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/62\" class=\"nounderline abstract_t\">Saueressig MG, Boussaud V, Amrein C, et al. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. Clin Transplant 2011; 25:E430.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/63\" class=\"nounderline abstract_t\">Lyu DM, Zamora MR. Medical complications of lung transplantation. Proc Am Thorac Soc 2009; 6:101.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/64\" class=\"nounderline abstract_t\">Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/65\" class=\"nounderline abstract_t\">Martin ST, Powell JT, Patel M, Tsapepas D. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept. Am J Health Syst Pharm 2013; 70:1977.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/66\" class=\"nounderline abstract_t\">Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(&#9733;). Am J Transplant 2011; 11:336.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/67\" class=\"nounderline abstract_t\">Knoop C, Kentos A, Remmelink M, et al. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission. Clin Transplant 2006; 20:179.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/68\" class=\"nounderline abstract_t\">Reynaud-Gaubert M, Stoppa AM, Gaubert J, et al. Anti-CD20 monoclonal antibody therapy in Epstein-Barr Virus-associated B cell lymphoma following lung transplantation. J Heart Lung Transplant 2000; 19:492.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/69\" class=\"nounderline abstract_t\">Raj R, Frost AE. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant 2005; 24:671.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/70\" class=\"nounderline abstract_t\">Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13:196.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/71\" class=\"nounderline abstract_t\">Milman N, Andersen CB, Burton CM, Iversen M. Recurrent sarcoid granulomas in a transplanted lung derive from recipient immune cells. Eur Respir J 2005; 26:549.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/72\" class=\"nounderline abstract_t\">Johnson BA, Duncan SR, Ohori NP, et al. Recurrence of sarcoidosis in pulmonary allograft recipients. Am Rev Respir Dis 1993; 148:1373.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/73\" class=\"nounderline abstract_t\">Yeatman M, McNeil K, Smith JA, et al. Lung Transplantation in patients with systemic diseases: an eleven-year experience at Papworth Hospital. J Heart Lung Transplant 1996; 15:144.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/74\" class=\"nounderline abstract_t\">Kazerooni EA, Jackson C, Cascade PN. Sarcoidosis: recurrence of primary disease in transplanted lungs. Radiology 1994; 192:461.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/75\" class=\"nounderline abstract_t\">Bj&oslash;rtuft O, Foerster A, Boe J, Geiran O. Single lung transplantation as treatment for end-stage pulmonary sarcoidosis: recurrence of sarcoidosis in two different lung allografts in one patient. J Heart Lung Transplant 1994; 13:24.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/76\" class=\"nounderline abstract_t\">Banga A, Sahoo D, Lane CR, et al. Disease Recurrence and Acute Cellular Rejection Episodes During the First Year After Lung Transplantation Among Patients With Sarcoidosis. Transplantation 2015; 99:1940.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/77\" class=\"nounderline abstract_t\">Nine JS, Yousem SA, Paradis IL, et al. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant 1994; 13:714.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/78\" class=\"nounderline abstract_t\">O'Brien JD, Lium JH, Parosa JF, et al. Lymphangiomyomatosis recurrence in the allograft after single-lung transplantation. Am J Respir Crit Care Med 1995; 151:2033.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/79\" class=\"nounderline abstract_t\">Sugimoto R, Nakao A, Yamane M, et al. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. J Heart Lung Transplant 2008; 27:921.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/80\" class=\"nounderline abstract_t\">Baz MA, Kussin PS, Van Trigt P, et al. Recurrence of diffuse panbronchiolitis after lung transplantation. Am J Respir Crit Care Med 1995; 151:895.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/81\" class=\"nounderline abstract_t\">Parker LA, Novotny DB. Recurrent alveolar proteinosis following double lung transplantation. Chest 1997; 111:1457.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/82\" class=\"nounderline abstract_t\">Santamaria F, Brancaccio G, Parenti G, et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. J Pediatr 2004; 145:268.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/83\" class=\"nounderline abstract_t\">King MB, Jessurun J, Hertz MI. Recurrence of desquamative interstitial pneumonia after lung transplantation. Am J Respir Crit Care Med 1997; 156:2003.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/84\" class=\"nounderline abstract_t\">Etienne B, Bertocchi M, Gamondes JP, et al. Relapsing pulmonary Langerhans cell histiocytosis after lung transplantation. Am J Respir Crit Care Med 1998; 157:288.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/85\" class=\"nounderline abstract_t\">Habib SB, Congleton J, Carr D, et al. Recurrence of recipient Langerhans' cell histiocytosis following bilateral lung transplantation. Thorax 1998; 53:323.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/86\" class=\"nounderline abstract_t\">Gabbay E, Dark JH, Ashcroft T, et al. Recurrence of Langerhans' cell granulomatosis following lung transplantation. Thorax 1998; 53:326.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/87\" class=\"nounderline abstract_t\">Dauriat G, Mal H, Thabut G, et al. Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006; 81:746.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/88\" class=\"nounderline abstract_t\">Paloyan EB, Swinnen LJ, Montoya A, et al. Lung transplantation for advanced bronchioloalveolar carcinoma confined to the lungs. Transplantation 2000; 69:2446.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/89\" class=\"nounderline abstract_t\">Wroblewski BM, Stefanovic CR, McDonough VM, Kidik PJ. The challenges of idiopathic pulmonary hemosiderosis and lung transplantation. Crit Care Nurse 1997; 17:39.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/90\" class=\"nounderline abstract_t\">Calabrese F, Giacometti C, Rea F, et al. Recurrence of idiopathic pulmonary hemosiderosis in a young adult patient after bilateral single-lung transplantation. Transplantation 2002; 74:1643.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/91\" class=\"nounderline abstract_t\">Frost AE, Keller CA, Brown RW, et al. Giant cell interstitial pneumonitis. Disease recurrence in the transplanted lung. Am Rev Respir Dis 1993; 148:1401.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/92\" class=\"nounderline abstract_t\">Mal H, Guignabert C, Thabut G, et al. Recurrence of pulmonary emphysema in an alpha-1 proteinase inhibitor-deficient lung transplant recipient. Am J Respir Crit Care Med 2004; 170:811.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/93\" class=\"nounderline abstract_t\">Banga A, Gildea T, Rajeswaran J, et al. The natural history of lung function after lung transplantation for &alpha;(1)-antitrypsin deficiency. Am J Respir Crit Care Med 2014; 190:274.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/94\" class=\"nounderline abstract_t\">Izbicki G, Shitrit D, Schechtman I, et al. Recurrence of pulmonary veno-occlusive disease after heart-lung transplantation. J Heart Lung Transplant 2005; 24:635.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/95\" class=\"nounderline abstract_t\">Arboleda R, Gonzalez O, Cortes M, Perez-Cerda F. Recurrent polymyositis-associated lung disease after lung transplantation. Interact Cardiovasc Thorac Surg 2015; 20:560.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/96\" class=\"nounderline abstract_t\">Collins J, Hartman MJ, Warner TF, et al. Frequency and CT findings of recurrent disease after lung transplantation. Radiology 2001; 219:503.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/97\" class=\"nounderline abstract_t\">Luckraz H, Zagolin M, McNeil K, Wallwork J. Graft-versus-host disease in lung transplantation: 4 case reports and literature review. J Heart Lung Transplant 2003; 22:691.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/98\" class=\"nounderline abstract_t\">Pfitzmann R, Hummel M, Grauhan O, et al. Acute graft-versus-host disease after human heart-lung transplantation: a case report. J Thorac Cardiovasc Surg 1997; 114:285.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/99\" class=\"nounderline abstract_t\">Chau EM, Lee J, Yew WW, et al. Mediastinal irradiation for graft-versus-host disease in a heart-lung transplant recipient. J Heart Lung Transplant 1997; 16:974.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/100\" class=\"nounderline abstract_t\">Worel N, Bojic A, Binder M, et al. Catastrophic graft-versus-host disease after lung transplantation proven by PCR-based chimerism analysis. Transpl Int 2008; 21:1098.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/101\" class=\"nounderline abstract_t\">Smith DM, Agura ED, Ausloos K, et al. Graft-vs-host disease as a complication of lung transplantation. J Heart Lung Transplant 2006; 25:1175.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/102\" class=\"nounderline abstract_t\">Singer SJ, Tiernan R, Sullivan EJ. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343:1815.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/103\" class=\"nounderline abstract_t\">Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77:1215.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/104\" class=\"nounderline abstract_t\">Morelon E, Stern M, Isra&euml;l-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72:787.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/105\" class=\"nounderline abstract_t\">Wang WL, Yu LX. Acute respiratory distress attributed to sirolimus in solid organ transplant recipients. Am J Emerg Med 2015; 33:124.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/106\" class=\"nounderline abstract_t\">Baas MC, Struijk GH, Moes DJ, et al. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int 2014; 27:428.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/107\" class=\"nounderline abstract_t\">Vlahakis NE, Rickman OB, Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 2004; 79:541.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/108\" class=\"nounderline abstract_t\">McWilliams TJ, Levvey BJ, Russell PA, et al. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 2003; 22:210.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/109\" class=\"nounderline abstract_t\">Lichtenstein GR, Kaiser LR, Tuchman M, et al. Fatal hyperammonemia following orthotopic lung transplantation. Gastroenterology 1997; 112:236.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/110\" class=\"nounderline abstract_t\">Tuchman M, Lichtenstein GR, Rajagopal BS, et al. Hepatic glutamine synthetase deficiency in fatal hyperammonemia after lung transplantation. Ann Intern Med 1997; 127:446.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/111\" class=\"nounderline abstract_t\">Lichtenstein GR, Yang YX, Nunes FA, et al. Fatal hyperammonemia after orthotopic lung transplantation. Ann Intern Med 2000; 132:283.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/112\" class=\"nounderline abstract_t\">Bharat A, Cunningham SA, Scott Budinger GR, et al. Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans. Sci Transl Med 2015; 7:284re3.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/113\" class=\"nounderline abstract_t\">Chen C, Bain KB, Iuppa JA, et al. Hyperammonemia Syndrome After Lung Transplantation: A Single Center Experience. Transplantation 2016; 100:678.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/114\" class=\"nounderline abstract_t\">Wylam ME, Kennedy CC, Hernandez NM, et al. Fatal hyperammonaemia caused by Mycoplasma hominis. Lancet 2013; 382:1956.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/115\" class=\"nounderline abstract_t\">Moffatt-Bruce SD, Pesavento T, Von Viger J, et al. Successful management of immunosuppression in a patient with severe hyperammonemia after lung transplantation. J Heart Lung Transplant 2008; 27:801.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/116\" class=\"nounderline abstract_t\">Anwar S, Gupta D, Ashraf MA, et al. Symptomatic hyperammonemia after lung transplantation: lessons learnt. Hemodial Int 2014; 18:185.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/117\" class=\"nounderline abstract_t\">Raghavan D, Gao A, Ahn C, et al. Contemporary analysis of incidence of post-operative atrial fibrillation, its predictors, and association with clinical outcomes in lung transplantation. J Heart Lung Transplant 2015; 34:563.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/118\" class=\"nounderline abstract_t\">Orrego CM, Cordero-Reyes AM, Estep JD, et al. Atrial arrhythmias after lung transplant: underlying mechanisms, risk factors, and prognosis. J Heart Lung Transplant 2014; 33:734.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/119\" class=\"nounderline abstract_t\">See VY, Roberts-Thomson KC, Stevenson WG, et al. Atrial arrhythmias after lung transplantation: epidemiology, mechanisms at electrophysiology study, and outcomes. Circ Arrhythm Electrophysiol 2009; 2:504.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/120\" class=\"nounderline abstract_t\">Saad M, Elgendy IY, Mentias A, et al. Incidence, Predictors, and Outcomes of Early Atrial Arrhythmias After Lung Transplant: A systematic review and meta-analysis. JACC Clin Electrophysiol 2017; 3:718.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/121\" class=\"nounderline abstract_t\">Henri C, Giraldeau G, Dorais M, et al. Atrial fibrillation after pulmonary transplantation: incidence, impact on mortality, treatment effectiveness, and risk factors. Circ Arrhythm Electrophysiol 2012; 5:61.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/122\" class=\"nounderline abstract_t\">Azadani PN, Kumar UN, Yang Y, et al. Frequency of atrial flutter after adult lung transplantation. Am J Cardiol 2011; 107:922.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/123\" class=\"nounderline abstract_t\">Gandhi SK, Bromberg BI, Mallory GB, Huddleston CB. Atrial flutter: a newly recognized complication of pediatric lung transplantation. J Thorac Cardiovasc Surg 1996; 112:984.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/124\" class=\"nounderline abstract_t\">Lee G, Wu H, Kalman JM, et al. Atrial fibrillation following lung transplantation: double but not single lung transplant is associated with long-term freedom from paroxysmal atrial fibrillation. Eur Heart J 2010; 31:2774.</a></li><li class=\"breakAll\">Ahya VN, Sager JS, Kotloff RM. Lung transplantation for pulmonary arterial hypertension. In: Pulmonary vascular disease, Mandel J, Taichman D (Eds), WB Saunders, Philadelphia 2006.</li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/126\" class=\"nounderline abstract_t\">Silverborn M, Jeppsson A, M&aring;rtensson G, Nilsson F. New-onset cardiovascular risk factors in lung transplant recipients. J Heart Lung Transplant 2005; 24:1536.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/127\" class=\"nounderline abstract_t\">Zanotti G, Hartwig MG, Castleberry AW, et al. Preoperative mild-to-moderate coronary artery disease does not affect long-term outcomes of lung transplantation. Transplantation 2014; 97:1079.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/128\" class=\"nounderline abstract_t\">Kamdar F, Hertz M, Shumway S, Missov E. Late effusive-constrictive pericarditis after lung transplantation. Am J Med 2015; 128:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/129\" class=\"nounderline abstract_t\">Karolak W, Cypel M, Chen F, et al. Constrictive pericarditis after lung transplantation: an under-recognized complication. J Heart Lung Transplant 2010; 29:578.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/130\" class=\"nounderline abstract_t\">Billings ME, Mulligan M, Raghu G, University of Washington Lung Transplant Team. Acute constrictive pericarditis after lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant 2009; 28:110.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/131\" class=\"nounderline abstract_t\">Afshar K, Cunningham MJ, Barbers RG, McFadden PM. Pericardial constriction after lung transplantation. Ann Thorac Surg 2010; 90:1361.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/132\" class=\"nounderline abstract_t\">Shields RK, Clancy CJ, Minces LR, et al. Epidemiology and outcomes of deep surgical site infections following lung transplantation. Am J Transplant 2013; 13:2137.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/133\" class=\"nounderline abstract_t\">Mitsani D, Nguyen MH, Silveira FP, et al. Mycoplasma hominis pericarditis in a lung transplant recipient: review of the literature about an uncommon but important cardiothoracic pathogen. Transpl Infect Dis 2010; 12:146.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/134\" class=\"nounderline abstract_t\">Levy PY, Habib G, Reynaud-Gaubert M, et al. Pericardial effusion due to Cryptococcus neoformans in a patient with cystic fibrosis following lung transplantation. Int J Infect Dis 2008; 12:452.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/135\" class=\"nounderline abstract_t\">Davidson JA, Wilkinson A, International Expert Panel on New-Onset Diabetes after Transplantation. New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. Diabetes Care 2004; 27:805.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/136\" class=\"nounderline abstract_t\">Ye X, Kuo HT, Sampaio MS, et al. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clin Transplant 2011; 25:885.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/137\" class=\"nounderline abstract_t\">Hackman KL, Snell GI, Bach LA. Prevalence and predictors of diabetes after lung transplantation: a prospective, longitudinal study. Diabetes Care 2014; 37:2919.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/138\" class=\"nounderline abstract_t\">Ollech JE, Kramer MR, Peled N, et al. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors. Eur J Cardiothorac Surg 2008; 33:844.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/139\" class=\"nounderline abstract_t\">Yusen RD, Christie JD, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age. J Heart Lung Transplant 2013; 32:965.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/140\" class=\"nounderline abstract_t\">Belle-van Meerkerk G, van de Graaf EA, Kwakkel-van Erp JM, et al. Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases. Diabet Med 2012; 29:e159.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/141\" class=\"nounderline abstract_t\">Hackman KL, Bailey MJ, Snell GI, Bach LA. Diabetes is a major risk factor for mortality after lung transplantation. Am J Transplant 2014; 14:438.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/142\" class=\"nounderline abstract_t\">Hoban R, Gielda B, Temkit M, et al. Utility of HbA1c in the detection of subclinical post renal transplant diabetes. Transplantation 2006; 81:379.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/143\" class=\"nounderline abstract_t\">Wehbe E, Brock R, Budev M, et al. Short-term and long-term outcomes of acute kidney injury after lung transplantation. J Heart Lung Transplant 2012; 31:244.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/144\" class=\"nounderline abstract_t\">Rocha PN, Rocha AT, Palmer SM, et al. Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortality. Am J Transplant 2005; 5:1469.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/145\" class=\"nounderline abstract_t\">Hellemons ME, Bakker SJ, Postmus D, et al. Incidence of impaired renal function after lung transplantation. J Heart Lung Transplant 2012; 31:238.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/146\" class=\"nounderline abstract_t\">Ishikawa S, Griesdale DE, Lohser J. Acute kidney injury within 72 hours after lung transplantation: incidence and perioperative risk factors. J Cardiothorac Vasc Anesth 2014; 28:931.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/147\" class=\"nounderline abstract_t\">Fidalgo P, Ahmed M, Meyer SR, et al. Incidence and outcomes of acute kidney injury following orthotopic lung transplantation: a population-based cohort study. Nephrol Dial Transplant 2014; 29:1702.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/148\" class=\"nounderline abstract_t\">George TJ, Arnaoutakis GJ, Beaty CA, et al. Acute kidney injury increases mortality after lung transplantation. Ann Thorac Surg 2012; 94:185.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/149\" class=\"nounderline abstract_t\">Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/150\" class=\"nounderline abstract_t\">Paradela de la Morena M, De La Torre Bravos M, Prado RF, et al. Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment. Transplant Proc 2010; 42:3217.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/151\" class=\"nounderline abstract_t\">Hellemons ME, Agarwal PK, van der Bij W, et al. Former smoking is a risk factor for chronic kidney disease after lung transplantation. Am J Transplant 2011; 11:2490.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/152\" class=\"nounderline abstract_t\">Kunst H, Thompson D, Hodson M. Hypertension as a marker for later development of end-stage renal failure after lung and heart-lung transplantation: a cohort study. J Heart Lung Transplant 2004; 23:1182.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/153\" class=\"nounderline abstract_t\">Broekroelofs J, Navis GJ, Stegeman CA, et al. Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss. Transplantation 2000; 69:1624.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/154\" class=\"nounderline abstract_t\">Al-Naamani N, Maarouf OH, Wilt JS, et al. The modification of diet in renal disease (MDRD) and the prediction of kidney outcomes after lung transplantation. J Heart Lung Transplant 2008; 27:1191.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/155\" class=\"nounderline abstract_t\">Osho AA, Castleberry AW, Snyder LD, et al. The Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) equation best characterizes kidney function in patients being considered for lung transplantation. J Heart Lung Transplant 2014; 33:1248.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/156\" class=\"nounderline abstract_t\">Thompson WM, Ho L, Marroquin C. Pneumatosis intestinalis and pneumoperitoneum after bilateral lung transplantation in adults. AJR Am J Roentgenol 2011; 196:W273.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/157\" class=\"nounderline abstract_t\">Mateen FJ, Dierkhising RA, Rabinstein AA, et al. Neurological complications following adult lung transplantation. Am J Transplant 2010; 10:908.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/158\" class=\"nounderline abstract_t\">Shigemura N, Sclabassi RJ, Bhama JK, et al. Early major neurologic complications after lung transplantation: incidence, risk factors, and outcome. Transplantation 2013; 95:866.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/159\" class=\"nounderline abstract_t\">Goldstein LS, Haug MT 3rd, Perl J 2nd, et al. Central nervous system complications after lung transplantation. J Heart Lung Transplant 1998; 17:185.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/160\" class=\"nounderline abstract_t\">Schuurmans MM, Tini GM, Zuercher A, et al. Practical approach to emergencies in lung transplant recipients: how we do it. Respiration 2012; 84:163.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/161\" class=\"nounderline abstract_t\">Aris RM, Neuringer IP, Weiner MA, et al. Severe osteoporosis before and after lung transplantation. Chest 1996; 109:1176.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/162\" class=\"nounderline abstract_t\">Shane E, Papadopoulos A, Staron RB, et al. Bone loss and fracture after lung transplantation. Transplantation 1999; 68:220.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/163\" class=\"nounderline abstract_t\">Spira A, Gutierrez C, Chaparro C, et al. Osteoporosis and lung transplantation: a prospective study. Chest 2000; 117:476.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/164\" class=\"nounderline abstract_t\">Yu TM, Lin CL, Chang SN, et al. Osteoporosis and fractures after solid organ transplantation: a nationwide population-based cohort study. Mayo Clin Proc 2014; 89:888.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/165\" class=\"nounderline abstract_t\">Singer LG, Brazelton TR, Doyle RL, et al. Weight gain after lung transplantation. J Heart Lung Transplant 2003; 22:894.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/166\" class=\"nounderline abstract_t\">Grady KL, Naftel D, Pamboukian SV, et al. Post-operative obesity and cachexia are risk factors for morbidity and mortality after heart transplant: multi-institutional study of post-operative weight change. J Heart Lung Transplant 2005; 24:1424.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/167\" class=\"nounderline abstract_t\">Williams JJ, Lund LH, LaManca J, et al. Excessive weight gain in cardiac transplant recipients. J Heart Lung Transplant 2006; 25:36.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/168\" class=\"nounderline abstract_t\">Raviv Y, D'Ovidio F, Pierre A, et al. Prevalence of gastroparesis before and after lung transplantation and its association with lung allograft outcomes. Clin Transplant 2012; 26:133.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/169\" class=\"nounderline abstract_t\">Lahon B, Mordant P, Thabut G, et al. Early severe digestive complications after lung transplantation. Eur J Cardiothorac Surg 2011; 40:1419.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/170\" class=\"nounderline abstract_t\">Paul S, Escareno CE, Clancy K, et al. Gastrointestinal complications after lung transplantation. J Heart Lung Transplant 2009; 28:475.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/171\" class=\"nounderline abstract_t\">Gilljam M, Chaparro C, Tullis E, et al. GI complications after lung transplantation in patients with cystic fibrosis. Chest 2003; 123:37.</a></li><li><a href=\"https://www.uptodate.com/contents/noninfectious-complications-following-lung-transplantation/abstract/172\" class=\"nounderline abstract_t\">Morton JR, Ansari N, Glanville AR, et al. Distal intestinal obstruction syndrome (DIOS) in patients with cystic fibrosis after lung transplantation. J Gastrointest Surg 2009; 13:1448.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4656 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H16568307\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H589167\" id=\"outline-link-H589167\">ALLOGRAFT REJECTION</a></li><li><a href=\"#H31532913\" id=\"outline-link-H31532913\">ANASTOMOTIC COMPLICATIONS</a><ul><li><a href=\"#H16568541\" id=\"outline-link-H16568541\">Airway anastomotic complications</a></li><li><a href=\"#H16568548\" id=\"outline-link-H16568548\">Vascular anastomotic complications</a><ul><li><a href=\"#H358248722\" id=\"outline-link-H358248722\">- Pulmonary artery stenosis</a></li><li><a href=\"#H358248728\" id=\"outline-link-H358248728\">- Kinking of the pulmonary artery</a></li><li><a href=\"#H358248790\" id=\"outline-link-H358248790\">- Pulmonary vein thrombosis</a></li></ul></li></ul></li><li><a href=\"#H31533024\" id=\"outline-link-H31533024\">PHRENIC NERVE AND DIAPHRAGMATIC DYSFUNCTION</a></li><li><a href=\"#H31533163\" id=\"outline-link-H31533163\">PLEURAL COMPLICATIONS</a></li><li><a href=\"#H588583\" id=\"outline-link-H588583\">PRIMARY GRAFT DYSFUNCTION</a></li><li><a href=\"#H31533170\" id=\"outline-link-H31533170\">VENOUS THROMBOEMBOLISM</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MALIGNANCY</a><ul><li><a href=\"#H23355512\" id=\"outline-link-H23355512\">Lung cancer</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">Posttransplantation lymphoproliferative disorders</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">RECURRENT PRIMARY DISEASE</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">GRAFT-VERSUS-HOST DISEASE</a></li><li><a href=\"#H11855970\" id=\"outline-link-H11855970\">DRUG-INDUCED PULMONARY TOXICITY</a></li><li><a href=\"#H31533290\" id=\"outline-link-H31533290\">EXTRAPULMONARY COMPLICATIONS</a><ul><li><a href=\"#H16568442\" id=\"outline-link-H16568442\">Hyperammonemia</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Cardiac complications</a></li><li><a href=\"#H11855898\" id=\"outline-link-H11855898\">Diabetes mellitus</a></li><li><a href=\"#H31532894\" id=\"outline-link-H31532894\">Renal insufficiency</a></li><li><a href=\"#H590353\" id=\"outline-link-H590353\">Pneumatosis intestinalis and pneumoperitoneum</a></li><li><a href=\"#H21179952\" id=\"outline-link-H21179952\">Neurologic complications</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Other complications</a></li></ul></li><li><a href=\"#H16568307\" id=\"outline-link-H16568307\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/4656|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/68233\" class=\"graphic graphic_table\">- Grading of acute GVHD</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=airway-complications-after-lung-transplantation\" class=\"medical medical_review\">Airway complications after lung transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=assessment-of-kidney-function\" class=\"medical medical_review\">Assessment of kidney function</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-infections-following-lung-transplantation\" class=\"medical medical_review\">Bacterial infections following lung transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=catheter-related-upper-extremity-venous-thrombosis\" class=\"medical medical_review\">Catheter-related upper extremity venous thrombosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-diagnosis-of-bilateral-diaphragmatic-paralysis\" class=\"medical medical_review\">Causes and diagnosis of bilateral diaphragmatic paralysis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-diagnosis-of-unilateral-diaphragmatic-paralysis-and-eventration-in-adults\" class=\"medical medical_review\">Causes and diagnosis of unilateral diaphragmatic paralysis and eventration in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chronic-lung-transplant-rejection-bronchiolitis-obliterans\" class=\"medical medical_review\">Chronic lung transplant rejection: Bronchiolitis obliterans</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-cytomegalovirus-infection-in-lung-transplant-recipients\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-deep-vein-thrombosis-of-the-lower-extremity\" class=\"medical medical_review\">Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-evaluation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-acute-pulmonary-embolism\" class=\"medical medical_review\">Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=constrictive-pericarditis\" class=\"medical medical_review\">Constrictive pericarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cyclosporine-and-tacrolimus-nephrotoxicity\" class=\"medical medical_review\">Cyclosporine and tacrolimus nephrotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-overview-of-gastrointestinal-disease\" class=\"medical medical_review\">Cystic fibrosis: Overview of gastrointestinal disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=development-of-malignancy-following-solid-organ-transplantation\" class=\"medical medical_review\">Development of malignancy following solid organ transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-evaluation-of-the-incidental-pulmonary-nodule\" class=\"medical medical_review\">Diagnostic evaluation of the incidental pulmonary nodule</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=differential-diagnosis-and-evaluation-of-multiple-pulmonary-nodules\" class=\"medical medical_review\">Differential diagnosis and evaluation of multiple pulmonary nodules</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-post-transplant-lymphoproliferative-disorders\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-treatment-of-acute-lung-transplant-rejection\" class=\"medical medical_review\">Evaluation and treatment of acute lung transplant rejection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-treatment-of-antibody-mediated-lung-transplant-rejection\" class=\"medical medical_review\">Evaluation and treatment of antibody-mediated lung transplant rejection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extracorporeal-membrane-oxygenation-ecmo-in-adults\" class=\"medical medical_review\">Extracorporeal membrane oxygenation (ECMO) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fungal-infections-following-lung-transplantation\" class=\"medical medical_review\">Fungal infections following lung transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=heart-lung-transplantation\" class=\"medical medical_review\">Heart-lung transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatic-encephalopathy-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Hepatic encephalopathy in adults: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipid-abnormalities-after-renal-transplantation\" class=\"medical medical_review\">Lipid abnormalities after renal transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=maintenance-immunosuppressive-therapy-in-renal-transplantation-in-adults\" class=\"medical medical_review\">Maintenance immunosuppressive therapy in renal transplantation in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mycoplasma-hominis-and-ureaplasma-urealyticum-infections\" class=\"medical medical_review\">Mycoplasma hominis and Ureaplasma urealyticum infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=new-onset-diabetes-after-transplant-nodat-in-renal-transplant-recipients\" class=\"medical medical_review\">New-onset diabetes after transplant (NODAT) in renal transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=osteoporosis-after-solid-organ-or-stem-cell-transplantation\" class=\"medical medical_review\">Osteoporosis after solid organ or stem cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-treatment-of-lower-extremity-deep-vein-thrombosis-dvt\" class=\"medical medical_review\">Overview of the treatment of lower extremity deep vein thrombosis (DVT)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-graft-versus-host-disease\" class=\"medical medical_review\">Pathogenesis of graft-versus-host disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=physiologic-changes-following-lung-transplantation\" class=\"medical medical_review\">Physiologic changes following lung transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pleural-complications-in-lung-transplantation\" class=\"medical medical_review\">Pleural complications in lung transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumatosis-intestinalis\" class=\"medical medical_review\">Pneumatosis intestinalis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-acute-graft-versus-host-disease\" class=\"medical medical_review\">Prevention of acute graft-versus-host disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-venous-thromboembolic-disease-in-surgical-patients\" class=\"medical medical_review\">Prevention of venous thromboembolic disease in surgical patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-lung-graft-dysfunction\" class=\"medical medical_review\">Primary lung graft dysfunction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-toxicity-associated-with-antineoplastic-therapy-molecularly-targeted-agents\" class=\"medical medical_review\">Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=renal-function-and-nonrenal-solid-organ-transplantation\" class=\"medical medical_review\">Renal function and nonrenal solid organ transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-post-transplant-lymphoproliferative-disorders\" class=\"medical medical_review\">Treatment and prevention of post-transplant lymphoproliferative disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-diaphragmatic-paralysis\" class=\"medical medical_review\">Treatment of diaphragmatic paralysis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-prognosis-and-follow-up-of-acute-pulmonary-embolism-in-adults\" class=\"medical medical_review\">Treatment, prognosis, and follow-up of acute pulmonary embolism in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=viral-infections-following-lung-transplantation\" class=\"medical medical_review\">Viral infections following lung transplantation</a></li></ul></div></div>","javascript":null}